SAN DIEGO, CA--(Marketwire - April 15, 2008) - Pre-clinical studies reviewed during an oral presentation here today at the annual meeting of the American Association for Cancer Research demonstrate that the Novogen drug candidate NV-128 engages a novel mode of cell death targeting the akt-mTOR pathway in multi-drug resistant ovarian cancer cells. The data were presented by Dr. Ayesha Alvero, MD, and Associate Professor Gil Mor, MD, Department of Obstetrics and Gynecology, Yale University School of Medicine.
